GlaxoSmithKline (GSK) Fined $3 Billion for Criminal and Civil Misconduct
This week, pharmaceutical giant GlaxoSmithKline (GSK: Charts, News) was fined $3 billion in the third largest health care fraud settlement in U.S. history. It is also the largest criminal-civil fine ever levied against a single drug company.
The majority of the wrongdoing spans between 1998 and 2007. Five years ago, (GSK: Charts, News) allowed the U.S. government to monitor its actions when allegations of misconduct initially arose. "Today brings to resolution difficult, long-standing matters for (GSK: Charts, News)," stated GlaxoSmithKline CEO Sir Andrew Witty. "Whilst these originate in a different era for the company, they cannot and will not be ignored." As part of the settlement, (GSK: Charts, News) has agreed to be monitored for five more years to ensure that further wrongdoing does not occur. Acting Assistant Attorney General Stuart F. Delery had stern words for the company. "For far too long, we have heard that the pharmaceutical industry views these settlements merely as the cost of doing business."
GlaxoSmithKline is not the first to face costly criminal and civil charges. In recent years, the pharmaceutical industry has undergone rapid consolidation, which has increased the stakes in a cutthroat game of acquiring the next hot product before existing patents expire. A popular tactic is to cozy up to well-reputed doctors to convince them to promote additional, unapproved uses for FDA approved medication - an illegal practice known as "off-label marketing". This strategy has helped many large pharmaceutical companies turn around poorly selling products into best-sellers. Prior to (GSK: Charts, News)'s record-setting fine, Pfizer PFI held the dubious title with its $2.3 billion fine to settle criminal and civil charges related to improperly marketing 13 different drugs, in addition to encouraging doctors to promote its products with resort packages and other perks.
(GSK: Charts, News) was found guilty of illegally using off-label marketing to promote two of its most popular products - Paxil and Wellbutrin. Paxil, an adult medication for depression, was illegally promoted to treat depression in children for five years, between 1998 and 2003. Wellbutrin, a medication for major depressive disorders, was also illegally promoted as a treatment for sexual dysfunction, substance addictions and ADHD, between 1999 and 2003. Between 2001 and 2007, (GSK: Charts, News) neglected to report safety data from its diabetes drug Avandia to the FDA, which was later found to increase the potential of congestive heart failure.
Other (GSK: Charts, News) products tainted by off-label marketing include Advair, Lamictal and Zofran. Advair has been a popular medication for mild asthma, although it was only approved for more serious cases. Lamictal, an epilepsy medication, was promoted as a treatment for psychiatric conditions and neuropathic pain. Zofran, a medication for post-operative nausea, was given to pregnant women to treat morning sickness.
These serious offenses have increased the Justice Department's role in prosecuting fraud in the pharmaceutical industry. Most major companies, including (GSK: Charts, News), have been brought down by whistleblowers. Groups of U.S. attorneys in Boston, Philadelphia and San Francisco - all pharmaceutical and biotech strongholds - have been particularly vigilant in taking on these whistleblower cases.
Despite pleading guilty and being charged $1 billion for criminal violations and $2 billion for civil ones, GlaxoSmithKline stated that the $3 billion settlement does "not constitute an admission of any liability or wrongdoing in the selling and marketing of (its products)." (GSK: Charts, News) also stated that the Justice Department's results "draw unwarranted conclusions from disputed facts."
Shares of (GSK: Charts, News) have been largely unaffected by the news. The stock is up 7% over the past twelve months, and has traded sideways for most of the past decade. (GSK: Charts, News) attracts income investors with its hefty dividend yield of nearly 5%, a common practice among pharmaceutical companies. The stock trades at 10.7 times forward earnings with a 5-year PEG ratio of 1.98.
Copyright 2012 by InvestorGuide.com, Inc. InvestorGuide has no control over the sites we link to, is not affiliated with these sites, and cannot take responsibility for their quality or suitability. The news, analysis, commentary and profile information is not meant to be comprehensive, and the data provided is not guaranteed to be accurate. WebFinance Inc., the publisher of this newsletter, is not a registered investment advisor or a broker/dealer. This is not a stock recommendation newsletter but rather a source for investment ideas, and we encourage you to fully research any company before considering investing. The opinions expressed herein are those of the author and do not necessarily represent the views of nor are they endorsed by WebFinance Inc.
No employee of WebFinance has owned or currently owns any shares in the company described above. The above is neither an offer nor solicitation to buy or sell any securities. The trading of securities may not be suitable for all potential readers of this newsletter, and the purchase of stocks mentioned in this newsletter may result in the loss of some or all of any investment made. We recommend that you consult a stockbroker or financial advisor before buying or selling securities or making investment decisions.
We are not responsible for claims made by advertisers and sponsors. Anyone who makes decisions based on what they read here does so at their own risk and cannot hold WebFinance Inc. (DBA InvestorGuide.com, Inc.) or its employees responsible.
Published on Jul 5, 2012By Leo Sun